South Korea
· Delayed Price · Currency is KRW HYUNDAI BIOLAND Statistics
Total Valuation
HYUNDAI BIOLAND has a market cap or net worth of KRW 152.70 billion. The enterprise value is 162.95 billion.
| Market Cap | 152.70B |
| Enterprise Value | 162.95B |
Important Dates
The next estimated earnings date is Monday, August 4, 2025.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
HYUNDAI BIOLAND has 30.00 million shares outstanding. The number of shares has increased by 49.94% in one year.
| Current Share Class | 30.00M |
| Shares Outstanding | 30.00M |
| Shares Change (YoY) | +49.94% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 1.84% |
| Float | 19.50M |
Valuation Ratios
The trailing PE ratio is 12.38 and the forward PE ratio is 8.98.
| PE Ratio | 12.38 |
| Forward PE | 8.98 |
| PS Ratio | 1.23 |
| PB Ratio | 1.19 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | 373.67 |
| P/OCF Ratio | 34.75 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.16, with an EV/FCF ratio of 398.76.
| EV / Earnings | -36.12 |
| EV / Sales | 1.31 |
| EV / EBITDA | 7.16 |
| EV / EBIT | 9.91 |
| EV / FCF | 398.76 |
Financial Position
The company has a current ratio of 2.99, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.99 |
| Quick Ratio | 1.06 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.64 |
| Debt / FCF | 35.69 |
| Interest Coverage | 30.81 |
Financial Efficiency
Return on equity (ROE) is 9.27% and return on invested capital (ROIC) is 6.53%.
| Return on Equity (ROE) | 9.27% |
| Return on Assets (ROA) | 5.96% |
| Return on Invested Capital (ROIC) | 6.53% |
| Return on Capital Employed (ROCE) | 12.56% |
| Revenue Per Employee | 388.79M |
| Profits Per Employee | -14.10M |
| Employee Count | 320 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.48 |
Taxes
In the past 12 months, HYUNDAI BIOLAND has paid 3.54 billion in taxes.
| Income Tax | 3.54B |
| Effective Tax Rate | 22.27% |
Stock Price Statistics
The stock price has decreased by -13.73% in the last 52 weeks. The beta is 0.75, so HYUNDAI BIOLAND's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -13.73% |
| 50-Day Moving Average | 4,431.60 |
| 200-Day Moving Average | 4,753.33 |
| Relative Strength Index (RSI) | 75.15 |
| Average Volume (20 Days) | 81,680 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HYUNDAI BIOLAND had revenue of KRW 124.41 billion and -4.51 billion in losses. Loss per share was -150.90.
| Revenue | 124.41B |
| Gross Profit | 54.39B |
| Operating Income | 16.44B |
| Pretax Income | 15.89B |
| Net Income | -4.51B |
| EBITDA | 22.75B |
| EBIT | 16.44B |
| Loss Per Share | -150.90 |
Balance Sheet
The company has 4.34 billion in cash and 14.59 billion in debt, giving a net cash position of -10.25 billion or -341.64 per share.
| Cash & Cash Equivalents | 4.34B |
| Total Debt | 14.59B |
| Net Cash | -10.25B |
| Net Cash Per Share | -341.64 |
| Equity (Book Value) | 128.18B |
| Book Value Per Share | 4,272.50 |
| Working Capital | 55.14B |
Cash Flow
In the last 12 months, operating cash flow was 4.39 billion and capital expenditures -3.99 billion, giving a free cash flow of 408.64 million.
| Operating Cash Flow | 4.39B |
| Capital Expenditures | -3.99B |
| Free Cash Flow | 408.64M |
| FCF Per Share | 13.62 |
Margins
Gross margin is 43.72%, with operating and profit margins of 13.21% and -3.63%.
| Gross Margin | 43.72% |
| Operating Margin | 13.21% |
| Pretax Margin | 12.77% |
| Profit Margin | -3.63% |
| EBITDA Margin | 18.29% |
| EBIT Margin | 13.21% |
| FCF Margin | 0.33% |
Dividends & Yields
This stock pays an annual dividend of 35.00, which amounts to a dividend yield of 0.69%.
| Dividend Per Share | 35.00 |
| Dividend Yield | 0.69% |
| Dividend Growth (YoY) | 100.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -49.94% |
| Shareholder Yield | -49.25% |
| Earnings Yield | -2.95% |
| FCF Yield | 0.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | May 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
HYUNDAI BIOLAND has an Altman Z-Score of 5.4 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.4 |
| Piotroski F-Score | 6 |